Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization
about
Discovery of a novel enzymatic cleavage site for botulinum neurotoxin F5Laboratory diagnostics of botulismGenomes, neurotoxins and biology of Clostridium botulinum Group I and Group IIEmerging opportunities for serotypes of botulinum neurotoxinsComparison and overview of currently available neurotoxinsMolecular evolution of antibody cross-reactivity for two subtypes of type A botulinum neurotoxinGlycosylated SV2 and Gangliosides as Dual Receptors for Botulinum Neurotoxin Serotype FStructure of dual receptor binding to botulinum neurotoxin BCrystal Structures of Botulinum Neurotoxin DC in Complex with Its Protein Receptors Synaptotagmin I and IICharacterization of botulinum neurotoxin type A neutralizing monoclonal antibodies and influence of their half-lives on therapeutic activityProduction and characterisation of a neutralising chimeric antibody against botulinum neurotoxin AAtoxic derivative of botulinum neurotoxin A as a prototype molecular vehicle for targeted delivery to the neuronal cytoplasmEnhanced neutralization potency of botulinum neurotoxin antibodies using a red blood cell-targeting fusion proteinAn assay for botulinum toxin types A, B and F that requires both functional binding and catalytic activities within the neurotoxin.Impact of Clostridium botulinum genomic diversity on food safety.Mechanisms of enhanced neutralization of botulinum neurotoxin by monoclonal antibodies conjugated to antibodies specific for the erythrocyte complement receptor.Toward low-cost affinity reagents: lyophilized yeast-scFv probes specific for pathogen antigens.Extraction and inhibition of enzymatic activity of botulinum neurotoxins/A1, /A2, and /A3 by a panel of monoclonal anti-BoNT/A antibodies.Fine and domain-level epitope mapping of botulinum neurotoxin type A neutralizing antibodies by yeast surface display.Sequencing the botulinum neurotoxin gene and related genes in Clostridium botulinum type E strains reveals orfx3 and a novel type E neurotoxin subtypeAnalysis of the neurotoxin complex genes in Clostridium botulinum A1-A4 and B1 strains: BoNT/A3, /Ba4 and /B1 clusters are located within plasmids.Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain.Thermostable llama single domain antibodies for detection of botulinum A neurotoxin complexEvidence that plasmid-borne botulinum neurotoxin type B genes are widespread among Clostridium botulinum serotype B strainsEpitope characterization and variable region sequence of f1-40, a high-affinity monoclonal antibody to botulinum neurotoxin type a (Hall strain).Llama single domain antibodies specific for the 7 botulinum neurotoxin serotypes as heptaplex immunoreagents.Affinity maturation of human botulinum neurotoxin antibodies by light chain shuffling via yeast mating.The case of botulinum toxin in milk: experimental dataConjugative botulinum neurotoxin-encoding plasmids in Clostridium botulinumUniversal and specific quantitative detection of botulinum neurotoxin genesGenomic sequences of six botulinum neurotoxin-producing strains representing three clostridial species illustrate the mobility and diversity of botulinum neurotoxin genesAnalysis of genomic differences among Clostridium botulinum type A1 strains.Botulinum neurotoxin D-C uses synaptotagmin I and II as receptors, and human synaptotagmin II is not an effective receptor for type B, D-C and G toxins.Tetanus neurotoxin utilizes two sequential membrane interactions for channel formation.Plasmidome interchange between Clostridium botulinum, Clostridium novyi and Clostridium haemolyticum converts strains of independent lineages into distinctly different pathogens.Two novel toxin variants revealed by whole-genome sequencing of 175 Clostridium botulinum type E strainsWhat next for botulism vaccine development?Pharmacophore Refinement Guides the Rational Design of Nanomolar-Range Inhibitors of the Botulinum Neurotoxin Serotype A MetalloproteaseAnalysis of a unique Clostridium botulinum strain from the Southern hemisphere producing a novel type E botulinum neurotoxin subtype.Neutralizing human monoclonal antibodies binding multiple serotypes of botulinum neurotoxin
P2860
Q24299963-A5A8A421-CDED-4D61-B5BF-30DB230E7580Q24545819-36220C01-9612-4850-A692-D85395BAC6C4Q26853403-5F783AB4-FA4E-497A-9DB2-9BE911CE6F31Q26859917-3933EB56-7D8E-4DBA-A35C-A24ED5A933DDQ27030752-209BC7DD-5458-4B31-8055-A53E2E1120BCQ27643327-2D03E32F-B766-4523-B586-5430DD74D69FQ27655649-F18EA591-EF25-44E3-82FB-B0344B472F5CQ27678834-A89763F9-0524-4BC1-8EF6-F540E4AC11AEQ27679493-E6B2A470-D652-4A8C-A538-4412BACDEBA3Q28475305-F2E5C9C2-00CA-4525-A091-0A2F07246536Q28475753-A64829C9-29D6-46F4-BC72-77EC2EA6D1A2Q28660367-B51A4232-F402-474F-AB2B-8220325AC2C5Q28742292-13559AC4-C1B2-43D8-8088-DF5F69313A71Q30228017-6C3213EE-C20C-43A7-B253-649F1AA7ADB8Q30239824-A423F4E0-D15D-4A69-ADA8-5F2E2C243BC8Q30408386-A62C6776-6ACA-4BD1-AD85-DBDAB21908B4Q30428279-C306C170-0720-44D1-B0EB-16CE420B7D6DQ30862040-694F58C0-F3E8-4DC8-A43B-0B03987AD845Q33261279-E12BBFFC-9FD2-4F5B-9FA4-6665B0F7F839Q33300918-47537F65-7778-4441-9B92-CEB6BADF5D1AQ33308728-456F981B-7D5E-4D82-86DA-3F6F087B0E94Q33361666-6BF20A01-C301-4BBE-AC68-45B8F1D5ED40Q33378940-D69EB27A-A531-44BE-A2EC-07D596E27A91Q33418275-96466CA7-21DA-4BFE-8113-D691E17836EAQ33418600-74DEEFA9-6134-4E40-918E-B9443A1CC15AQ33526251-43B17F60-C84A-4BE5-BF35-F7D19C4FEC39Q33531378-4BEFD14C-A623-4EC0-BB07-E8D1BF6BA283Q33549116-C1B1C47F-D82E-4F06-AE4B-F81E0738CB7EQ33605741-6634D31A-270E-4283-884C-FC088133AC45Q33723538-61ADAF1A-1E76-4310-8E55-5F3D8ADFA409Q33764443-182F1111-E2DD-4CBD-81F1-0044D081CD3DQ33779572-516003CA-1788-428D-A9F5-8A74E3592B48Q33793263-32A272F9-71A1-4EB8-A900-6609D057718FQ34070484-47A2924A-090A-4CEC-B3B1-A20019C5EFF7Q34257215-728C06B5-463C-458F-BDD1-B54590885E4FQ34261184-D7D0EC10-CAA6-40E2-802B-7882B8FFE018Q34343808-64FB7477-258B-4C5D-8F96-BE6C71756C89Q34353299-1F38FB96-D2CE-4A42-900E-EAB6FA618E57Q34462614-A59EB219-8403-47E0-8217-C7A87C593C47Q34571717-D598124D-F491-4C53-9F5B-5FAE1DC5C28F
P2860
Sequence variation within botulinum neurotoxin serotypes impacts antibody binding and neutralization
description
2005 nî lūn-bûn
@nan
2005 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Sequence variation within botu ...... ody binding and neutralization
@ast
Sequence variation within botu ...... ody binding and neutralization
@en
Sequence variation within botu ...... ody binding and neutralization
@nl
type
label
Sequence variation within botu ...... ody binding and neutralization
@ast
Sequence variation within botu ...... ody binding and neutralization
@en
Sequence variation within botu ...... ody binding and neutralization
@nl
prefLabel
Sequence variation within botu ...... ody binding and neutralization
@ast
Sequence variation within botu ...... ody binding and neutralization
@en
Sequence variation within botu ...... ody binding and neutralization
@nl
P2093
P2860
P1476
Sequence variation within botu ...... ody binding and neutralization
@en
P2093
C M Forsyth
E A Johnson
M Bradshaw
S L Laporte
P2860
P304
P356
10.1128/IAI.73.9.5450-5457.2005
P407
P577
2005-09-01T00:00:00Z